NUVATION BIO INC CLASS A (NUVB)
Health Care · Oncology / targeted small-molecule therapeutics · NYSE
A recently commercialized, oncology-focused biotech leveraging deep medicinal chemistry expertise to develop targeted small-molecule cancer therapies, with its first marketed product taletrectinib already approved in the U.S., Japan, and China for ROS1-positive lung cancer.
What NUVATION BIO INC CLASS A does
Nuvation Bio is a global oncology company founded in 2018 by the creator of Xtandi® and Talzenna® that develops novel small-molecule targeted cancer therapies. The company leverages expertise in medicinal chemistry and drug development to pursue validated oncology targets with the goal of improving safety and efficacy over existing treatments. Nuvation Bio commercially launched IBTROZI (taletrectinib) in the U.S. in June 2025 for ROS1-positive non-small cell lung cancer and is advancing a pipeline of clinical-stage oncology candidates including safusidenib for IDH1-mutant glioma.
Themes: ["Targeted cancer therapeutics","ROS1-driven NSCLC","IDH1-mutant glioma","Small-molecule inhibitors","Rare/orphan oncology indications"]
Fundamentals
- Price$6.11 as of 2026-07-09 close
- Market cap$2.0B as of 2026-07-10
- 1-year return+157.8% as of 2026-07-09 close
- Net margin-102.1% as of 2026-07-10
- Gross margin+90.8% as of 2026-07-10
- ROE-44.1% as of 2026-07-10
- Debt / equity0.67 as of 2026-07-10
- Revenue growth (YoY)+1205.5% as of 2026-07-10
- Beta1.52 as of 2026-07-10
Key risks (from latest filing)
["Taletrectinib (IBTROZI) is a newly commercialized product with limited market penetration history and revenue generation; commercial success is unproven and subject to market adoption, physician adoption, and reimbursement challenges","The company is unprofitable with significant ongoing R&D and clinical trial expenses; continued funding will be required to advance pipeline candidates through development and commercialization","Clinical development risk: safusidenib SIGMA Phase 3 study outcomes and regulatory approval are uncertain; failure or delays could materially impact the pipeline"]
Competitors & peers
- Ignyta (acquired by Genentech/Roche for crizotinib)
- Novartis - ROS1 and ALK targeted oncology programs
- Roche/Genentech - targeted NSCLC therapies
- Bristol Myers Squibb - targeted oncology portfolio
- Pfizer - broad oncology platform (CEO's prior company)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.